Dr. Khalifa is the Donald F. Gleason Professor and Director of Anatomic Pathology and a member of the Division of Molecular Pathology and Genomics. He conducts clinical and translational research in gynecologic, hepato-biliary and gastrointestinal disease including cancer using immunohistochemical techniques. The growing number of well-defined tumor antibodies and biomarkers enables surgical pathologists to make a diagnosis with ever-greater accuracy. Antibodies and biomarkers also can provide prognostic information for how a tumor may progress and respond to treatment.
Khalifa MA, Gagner B, Chen L, Murugan P, Klein ME, Racila E, Amin K, Miller F, Stewart J, Ding Y, Farooqui M, Dasaraju S, and Adeyi OA. Immunohistochemistry and immunofluorescence utilization audit by subspecialty in an academic setting: A step toward stewardship. Annals of Diagnostic Pathology, Volume 67, 2023, 152214, https://doi.org/10.1016/j.anndiagpath.2023.152214.
Clemente V, Hoshino A, Shetty M, , Erickson BK, Baker R, Rubin N, Khalifa M, Weroha SJ, Lou E, Bazzaro M.GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors. Cancer Research Communications, July 18, 2022.https://doi.org/10.1158/2767-9764.CRC-22-0122
Bedell S, Chang Z, Burt C, Khalifa M, and Argenta P. Incisional carcinoma of mullerian origin: A case report and review of literature. Gynecologic Oncology Reports, 2000; 33. 100588. 10.1016/j.gore.2020.100588.
Erickson BE, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, and Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology, 2020; 159 (1): 17-22. https://doi.org/10.1016/j.ygyno.2020.07.016.
Wilhite AM, Oestreich MC, Olson M, Bedell SM, Westenberg D, Bangdiwala A, Ikramuddin S, Sanchez-Avila M, Madoff RD, Khalifa MA, Erickson BK. Health care health care provider adherence to surgical guidelines for risk reducing salpingo-oophorectomy. Obstetrics & Gynecology 2019;134: 520-526.
Glasgow MA, Argenta P, Abrahante JE, Shetty M, Talukdar S, Croonquist PA, Khalifa MA, Starr TK. “Biological insights into chemotherapy resistance in ovarian cancer.” Int J Mol Sci. 2019 Apr 30;20(9):2131.
Bassiouny D, Ismiil N, Dubé V, Han G, Cesari M, Lu F-I, Slodkowska E, Parra-Herren C, Chiu HF, Naeim M, Li N, Khalifa M, Nofech-Mozes S. Comprehensive clinicopathologic and updated immunohistochemical characterization of primary ovarian mucinous carcinoma. In J Surg Pathol 2018;1.
Fellowships, Residencies, and Visiting Engagements
AddressRm C446-1 Mayo
420 Delaware St. SE
Minneapolis, MN 55455